Carotenoid profile in grapes related to aromatic compounds in wines from Douro region

The aim of this work was to characterize 8 representative grape varieties of the Douro Region using the carotenoid profile as it relates to aromatic compounds in the respective wines. Some other analyses, such as the determination of sugar, probable alcohol, pH, and total acidity, were also performed in an attempt to understand in which way the evaluated characteristics influenced by grape variety could contribute to the wine aroma. For the 3 y of the study, grape varieties with higher concentrations of carotenoids (Touriga Fêmea, Tinta Amarela, and Tinta Barroca) have lower values of free norisoprenoids, even with exceptions (Touriga Fêmea). Conversely, grape varieties with lower concentrations of carotenoids (Touriga Nacional, Sousão, and Tinto Cão) appear to have higher contents of free norisoprenoids, namely b-ionone for Touriga Nacional and vitispirane and 1,1,6-trimethyl-1,2- dihydronaphthalene (TDN) for Sousão and Tinto Cão. Touriga Nacional, followed by Touriga Fêmea, was the wine variety with the highest values of total free terpenols (linalol, a-terpineol, nerol, and geraniol), the presence of which is responsible for the floral aroma

Educação ambiental nos anos iniciais do ensino fundamental em escolas públicas urbanas do oeste do Paraná

Resumo: A Política Nacional de Educação Ambiental (PNEA) postula que a Educação Ambiental (EA) deve ser trabalhada de forma permanente e interdisciplinar. Assim, o objetivo deste trabalho foi verificar se as ações de EA desenvolvidas nas escolas de um município do estado do Paraná seguem as diretrizes do PNEA, e quais vertentes da EA estão sendo trabalhadas com mais frequência. A metodologia de caráter quali-quantitativa consistiu na aplicação de um questionário aos professores de Ciências do Ensino Fundamental Inicial das três escolas urbanas do município. Os resultados mostraram que, para se adaptar ao PNEA, as escolas precisam incluir a EA no período de planejamento dos professores, ampliando os esforços de interdisciplinaridade e incentivar a participação da comunidade. Verificou-se, ainda, que as abordagens Conservacionista e Pragmática são mais empregadas do que a abordagem Crítica, assim, é importante inserir mais ações voltadas para EA Crítica no planejamento curricular, contribuindo para seu desenvolvimento prático.Palavras-chave: Educação Ambiental; PNEA; Ensino de Ciências. Environmental education in the urban public elementary school in west of ParanáAbstract: The National Environmental Education Policy (PNEA) postulates that Environmental Education (EE) must be worked in a permanent and interdisciplinary way. Thus, the objective of this work was to verify whether the EE actions developed in schools in a municipality in the Paraná (Brazil) follow the guidelines of the PNEA, and which aspects of the EE are more frequent. The qualitative and quantitative methodology consisted of the application of a questionnaire to teachers of Sciences of the Elementary Education of the three urban schools. The results showed that, in order to adapt to the PNEA, schools need to include EE in the planning period of teachers, expanding interdisciplinary efforts and encouraging community participation. It was also verified that the Conservationist and Pragmatic approaches are more used than the Critical approach, therefore, it is important to insert more actions focused on Critical EE in the curricular planning, contributing to its practical development.Keywords: Environmental Education; PNEA; Elementary School.

Neuroproteção na ressecção cirúrgica de gliomas cerebrais: revisão da evidência atual

Os gliomas cerebrais são tumores primários do sistema nervoso central que se desenvolvem a partir de células gliais e têm alta morbimortalidade. Seu tratamento padrão envolve a ressecção cirúrgica, radioterapia e quimioterapia, os quais possivelmente podem levar os pacientes a um prognóstico desfavorável. Nesse contexto, a neuroproteção entra como uma aliada para minimizar os efeitos colaterais da ressecção cirúrgica e melhorar a sobrevida e a qualidade de vida dos pacientes. Nesse sentido, o presente estudo tem como objetivo discutir sobre a evidência atual da neuroproteção na ressecção cirúrgica de gliomas cerebrais. Para isso, foram selecionados quatro artigos que que abordavam sobre a evidência atual da neuroproteção na ressecção cirúrgica de gliomas cerebrais, por meio de uma estratégia de busca com recorte temporal entre 2014 e 2023, nas bases de dados PubMed (Medline), Embase e Cochrane Library. Os resultados indicam que o grupo de pacientes que recebeu dexmedetomidina apresentou melhora significativa na cognição e redução da inflamação cerebral em comparação com o grupo-controle pós-ressecção dos gliomas cerebrais, além de menor incidência de efeitos colaterais anestésicos, como náusea e vômitos (p < 0,05). Ademais, foi observado que a modulação da via metabólica do glutamato/glutamina pode inibir o crescimento de gliomas e proteger o parênquima cerebral. Nesse sentido, as evidências atuais indicam que proteger as células nervosas é uma estratégia importante para minimizar os efeitos colaterais da ressecção cirúrgica de gliomas cerebrais, e a dexmedetomidina e a co-cultura de células de glioma e astrócitos que aumenta a concentração extracelular de glutamato e glutamina parecem ser importantes aliadas nessa profilaxia

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

The influence of selected oenological practices on the sensory impact of volatile phenols in red wines

Aims: Volatile phenols (4-ethylphenol and 4-ethylguaiacol) affect wine quality by imparting, above certain concentrations, aroma defects. This work aimed to evaluate the effect of some common oenological practices on the concentration of volatile phenols and the sensory impact of these odour-active compounds in wines. Methods and results: The studied oenological practices were based on the addition of gum arabic, mannoproteins, yeast cell walls, lees, oak chips, dairy cream and potassium caseinate and on the application of a bubbled nitrogen stream. These treatments were applied to naturally contaminated wines containing volatile phenols at concentrations above detection threshold. The treated wines were characterised by chemical and sensory analysis. The most effective treatments in the reduction of the concentration of volatile phenols were the addition of fine lees, cream and potassium caseinate. Apart from being able to partially remove these compounds (approximately 35% removal), fine lees contributed to a greater “freshness” and complexity of the wines. Although the addition of cream did decrease the sensory impact of volatile phenols, it did not benefit the wines as these were strongly marked by dairy aromas. The use of oak chips, although it did not have a notable effect on the removal of volatile phenols, led to a significant reduction in the perception of these compounds. Conclusions: It is demonstrated that certain oenological practices may decrease the impact of volatile phenols in red wines. Significance and impact of the study: Solutions, particularly applicable in a winemaking environment, are suggested to the wine industry

Aprendizagem Infantil na 4ª série volume 3, 1925, Minas Gerais

O livro é de 1925, capa dura, possui 899 páginas e ilustrações demonstradas como desenhos realizados por Eraldo Faria. Ele está disponível em três unidades sobre os quais os temas são: Energia, Região Nordeste e Região Norte. Esse livro foi encontrado com a professora Vicentina da Conceição Alves dos Santos em São José das Três Ilhas, Minas Gerais. E cedido ao Grupo de História da Educação Matemática – Juiz de Fora, coordenado pela professora Maria Cristina Araújo de Oliveira, para digitalização.O livro é iniciado na 4ª unidade com o título de Algumas formas de Energia e como utilizamos. A unidade relata atividades variadas de formas de energia como: carvão, petróleo, pilha, luz elétrica, ímãs e eletromagnetismo disponíveis no formato de plano de aula. Dando prosseguimento, o livro aborda Linguagem como continuação a partir do desenvolvimento da leitura e promoção da significação das palavras levando em consideração o assunto energia citada anteriormente. A 5ª unidade presente no mesmo evidencia a Região Nordeste com: características físicas, áreas, habitantes, colonização, economia e aspectos históricos. Já a 6ª unidade realiza as mesmas citações sobre a Região Norte

Data publication with the structural biology data grid supports live analysis.

Access to experimental X-ray diffraction image data is fundamental for validation and reproduction of macromolecular models and indispensable for development of structural biology processing methods. Here, we established a diffraction data publication and dissemination system, Structural Biology Data Grid (SBDG; data.sbgrid.org), to preserve primary experimental data sets that support scientific publications. Data sets are accessible to researchers through a community driven data grid, which facilitates global data access. Our analysis of a pilot collection of crystallographic data sets demonstrates that the information archived by SBDG is sufficient to reprocess data to statistics that meet or exceed the quality of the original published structures. SBDG has extended its services to the entire community and is used to develop support for other types of biomedical data sets. It is anticipated that access to the experimental data sets will enhance the paradigm shift in the community towards a much more dynamic body of continuously improving data analysis